Seven capsules — patient selection, training, regulation, decision support, and a working developer engine — built around stromal vascular fraction. Bilingual. Bedside-ready. Built for the partners who ship cell therapy at scale.
The complete platform — six clinical-license capsules plus the master overview — delivered as a single self-contained download. Use it inside your clinic, your training programme, or your next trial. Built for partners who ship cell therapy at scale.
A kit alone teaches no one. The clinic that buys it inherits a hundred unanswered questions — which patients qualify, which contraindications are absolute, what the consent must include, how follow-up is captured, what the registry looks like, what the regulator allows.
The SVF Clinical Platform is the layer that sits between the kit and the patient. Seven capsules, one shared logic, and a working developer engine for anyone who wants to turn cell biology into software.
The platform synthesises the major systematic reviews on adipose-derived therapies — Lana 2022, Goncharov 2023, Hohmann 2025 — and the most recent literature on niche reconstruction in bone, cartilage, and soft-tissue regeneration.
Each capsule is engineered as an independent surface, yet all seven share one common clinical logic — the same patient-selection grammar, the same safety frame, the same registry vocabulary. The result is a platform that a partner can adopt whole, fork into a private edition, or absorb into an existing product line under their own brand.
Built by a clinical regenerative medicine team across a year of reading, modelling, and capsule iteration — designed for the partners who ship cell therapy at scale.